AI Article Synopsis
- A study examined how sera from patients with paroxysmal nocturnal hemoglobinuria (PNH) and normal individuals affect the growth of single CD34(+) cells.
- The results showed no significant differences in growth between normal and PNH CD34(+) cells when using either type of serum in both single cell and colony formation cultures.
- However, PNH sera seemed to enhance colony formation for CD34(+) CD59(+) cells in semi-solid cultures compared to the serum from normal individuals.
Article Abstract
To investigate the effects of sera on the growth of single CD34(+) cells from patients with paroxysmal nocturnal hematoglobinuria (PNH), sera from both PNH patients and normal individuals were added separately to the single cell culture system and semi-solid colony formation system. The growth of the normal CD34(+) and PNH CD34(+) CD59(+) and CD34(+) CD59(-) cells was evaluated. No growth difference was found for growth of the normal CD34(+) and PNH CD34(+) CD59(+) cells when PNH or normal sera were added to the culture media in either single cell culture or colony formation culture. While no difference was detected for single PNH CD34(+) CD59(-) cells growth when PNH or normal sera were added, more colonies were observed in semi-solid culture with PNH sera. A conclusion was reached that compared with those from normal controls, the sera from PNH patients had no significant influence on single hematopoietic stem/progenitor cells derived from normal subjects and from PNH patients, but the PNH sera might promote the colony formation of the CD34(+) CD59(+) cells in semi-solid culture
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Drugs R D
December 2024
Swedish Orphan Biovitrum AB, Stockholm, Sweden.
Article Synopsis
- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder that can cause severe hemolysis and blood clots, and the new therapy pegcetacoplan aims to improve patient outcomes by targeting both types of hemolysis.
- The analysis of data from clinical studies showed that administering pegcetacoplan at a dose of 1080 mg twice weekly resulted in effective and stable levels in the body, along with significant improvements in blood biomarkers related to hemolysis within four weeks.
- Factors such as body weight and previous treatments influenced drug exposure and responses, but these effects were not significant enough to alter treatment effectiveness, supporting the approved dosage for optimal patient care.
Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus.
Int J Mol Sci
November 2024
Cancer Center, Division of Hematology and Oncology, Department of Medicine, Taipei Municipal Wanfang Hospital, Taipei Medical University, No. 111, Section 3, Xinglong Rd, Wenshan District, Taipei City 11696, Taiwan.
Paroxysmal nocturnal hemoglobinuria (PNH) clones can be identified in a significant proportion of patients with aplastic anemia (AA). Screening for PNH clones at the time of an AA diagnosis is recommended by national and international guidelines. In this report, an expert panel of physicians discusses current best practices and provides recommendations for managing PNH in patients with AA in the Asia-Pacific region.
View Article and Find Full Text PDF[Acquired bone marrow aplasia in children and young adults under the age of 30: Experience of the Pediatric Hematology and Oncology Department of the 20 August Hospital, Casablanca].
Bull Cancer
October 2024
Service d'hématologie clinique et d'oncologie pédiatrique, faculté de médecine et de pharmacie de Casablanca, centre hospitalier universitaire 20 Août de Casablanca, Casablanca, Maroc.
Bone marrow aplasia is a rare and serious hematologic disorder. Although benign, it is a hematologic disorder whose prognosis can be poor and whose spontaneous development can be fatal. Treatment is long, difficult and costly.
View Article and Find Full Text PDFPharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
Blood Adv
June 2024
Department of Haematology, King's College Hospital, National Institute of Health Research/Wellcome King's Clinical Research Facility, King's College London, London, United Kingdom.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disease of uncontrolled terminal complement activation leading to intravascular hemolysis, thrombotic events and increased morbidity and mortality. This phase 3, open-label, single-arm, multicenter study evaluated ravulizumab treatment in eculizumab-naive or -experienced pediatric patients (aged <18 years) with PNH over a 26-week primary evaluation period (PEP) and 4-year extension period (EP). Patients included in the study received weight-based intravenous ravulizumab dosing.
View Article and Find Full Text PDFCase report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria.
Front Immunol
January 2024
Department of Hematology, Kanazawa University, Kanazawa, Japan.
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disease characterized by intravascular hemolysis, thrombosis, and bone marrow (BM) failure. Although PNH is caused by excessive proliferation of hematopoietic stem cell (HSC) clones with loss of function mutations in phosphatidylinositol N-acetylglucosaminyltransferase subunit A () genes, what drives PNH clones to expand remains elusive.
Case Description: We present a case of a 26-year-old female who presented with hemolytic anemia, thrombocytopenia, and leukopenia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!